Abstract
Binge-eating disorder, which is characterized by repeated episodes of uncontrolled eating, is common in obese patients and is often accompanied by comorbid psychiatric disorders, especially depression. In previous studies, selective serotonin reuptake inhibitors have demonstrated efficacy in reducing the frequency of binge eating and addressing comorbid psychiatric disorders, but they have not shown the ability to promote weight loss. Sibutramine, a new serotonin and norepinephrine reuptake inhibitor, has been shown in short- and long-term studies to be effective in promoting and maintaining weight loss in obese patients who have binge-eating disorder. In this randomized, double-blind, placebo-controlled study, the efficacy, safety, and tolerability of sibutramine were evaluated in the treatment of binge-eating disorder in obese patients. Twenty patients were randomly assigned in equal numbers to receive either sibutramine 10 mg/day or placebo for 12 weeks. Assessments were made at baseline and every 2 weeks throughout the study. Binge frequency, defined as the number of days during the previous week that included binge-eating episodes, was the primary outcome measure. By the end of the study, the binge frequency among patients given sibutramine was significantly lower than that among those given placebo. The main adverse events in the sibutramine group were dry mouth and constipation. The findings suggest sibutramine is an effective medication in the treatment of binge-eating disorders and is well tolerated. In addition, it addresses the 3 main goals in the treatment of binge-eating disorder: reducing the frequency of binge eating, promoting and maintaining weight loss, and treating the comorbid psychiatric conditions.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Muscettola G, Casiello M. Psicofarmacologia dei disordini del comportamento alimentare. In: Bellantuono C, Balestrino M, eds.Gli psicofarmaci: farmacologia e terapia. Rome, Italy: Il Pensiero Scientifico Editore; 1997:13–24.
American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994.
Walsh T, Devlin M. Eating disorders: progress and problems.Science. 1998;280:1387–1390.
Cuzzolaro M, Magnani M. Obesità e disturbi del comportamento alimentare. In: Borsello O, ed.Obesità. Milan, Italy: Editrice Kurtis;1998:16–22.
Bellodi L, Brambilla F. Eating Disorders and Obsessive Compulsive Disorder: An Etiopathogenetic Link? Torino, Italy: Centro Scientifio Editore. 1999.
Walsh BT. Binge eating in bulimia nervosa. In: Fairburn CG, Wilson GT, eds.Binge Eating: Nature, Assessment and Treatment. New York, NY: Guilford Press;1993:60–51.
Stunkard AJ. Some perspectives on human obesity: its causes.Bull N Y Acad Med. 1988;64:902–911.
Stunkard AJ. Binge eating disorder and the treatment of obesity.Obese Res. 1991;2:279–283.
Yanoski SZ, Nelson JE, Dubbert B, Spitzer RL. Binge eating disorder is associated with psychiatric comorbidity in the obese.Am J Psychiatry. 1993;150:1472–1479.
Stuart RR. Behavioural control of overeating.Behav Res Ther. 1967;5:357–364.
Ricca V, Mannucci E, Di Bernardo M. Disturbo da Alimentazione Incontrollata [Binge Eating Disorder].Giornale Italiano di Psicopatologia. 1998;2:223–239.
Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders.Psychoneuroendocrinology. 1995;20:561–590.
Ramacciotti C. Terapia farmacologica della bulimia nervosa e del BED. In: Cuzzolaro M, ed.Terapia farmacologica dei disturbi del comportamento alimentare. Editrice Kurtis; 2000:30–35.
Leibowitz SF, Shor-Posner G. Brain serotonin and eating behavior.Appetite. 1986;7(suppl):1–14.
Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM. Decreased serotonin function in bulimia nervosa.Arch Gen Psychiatry. 1997;54:529–534.
Muller E, Brambilla F.Disordini del comportamento alimentare. Milan, Italy: Pythagora Press; 1997.
Devane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors.Human Psychopharmacol. 1995;10(suppl 3):S185-S193.
American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (revision). American Psychiatric Association Work Group on Eating Disorders.Am J Psychiatry. 2000;157(suppl 1):1–39.
Kay WH. Serotonin regulation in bulimia. In: Hudson J, Pope H Jr, eds.The Psychobiology of Bulimia. Washington, DC: APA Press; 1987.
Buckett WR, Thomas PG, Luscombe GP. The pharmacology of sibutramine hydrochloride, a new antidepressant which induces rapid noradrenergic down-regulation.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584.
Stricker-Krongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity role of dietary constituents.Int J Obes. 1995;19:P399.
Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss.Obes Res. 1999;7:189–198.
Cole JO, Kaiser PE, DeHaan HA. Sibutramine hydrochloride: evaluation of abuse potential.Obes Res. 1991;1(suppl 2):145.
Weintraub M, Rubio A, Golik A, Byrne L, Scheinbum ML. Sibutramine in weight control: a dose-ranging efficacy study.Clin Pharmacol Ther. 1991;50:330–337.
Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.Obes Rev. 2000;1:127–139.
Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation.Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584.
Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.J Pharmacol Exp Ther. 1997; 283:581–591.
Stricker-Krograd A, Burlet C, Souqurt AM. Effects of sibutramine on feeding behaviour in dietary-induced obesity: a role of dietary components.Int J Obes. 1995;19(suppl 12):145.
Kaiser PE, Hinson JL. Sibutramine: dose response and plasma metabolic concentrations in weight loss.J Clin Pharmacol. 1994;34:1019.
Van Gaal LF, Wauters MA De, Leew IH. Anti-obesity drugs, what does sibutramine offer? An analysis of its potential contribution of obesity treatment.Exp Clin Endocrinol Diabetes. 1998;106:35–40.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milano, W., Petrella, C., Casella, A. et al. Use of sibutramine an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study. Adv Therapy 22, 25–31 (2005). https://doi.org/10.1007/BF02850181
Issue Date:
DOI: https://doi.org/10.1007/BF02850181